|
Ilona Reischl PhD
Chair
EMA Committee for Advanced Therapies
Austria
|
Ilona Reischl joined the Austrian Medicines and Medical Devices Agency AGES MEA in March 2006 and has been affiliated with the Clinical Trials Unit since then and as head of unit until 2019. This division in the Institute Surveillance is responsible for clinical trials with medicinal products or medical devices and GCP inspections. She remains active as quality assessor but since 2019 has focused on tasks on the European level.
A PhD in immunology/allergology followed the initial degree in pharmacy, thereafter postdoctoral experience at an industrial research institute (AT), at the University of Southampton (UK) and at the National Institutes of Health (USA). The focus on the regulatory role started with a dual research/regulatory position at the US Food and Drug Administration (FDA).
Ilona Reischl has been the longstanding Austrian member of the European Medicines Agency Biologics Working Party and the Committee for Advanced Therapies, where she has been elected as chair in 2023. A keen interest in innovation has led to active involvement in manufacturing, procedural and scientific issues pertaining to biotech products in general and ATMPs in particular. Current additional regulatory activities focus on the interface of medicinal products and medical devices, including in vitro diagnostics during the life-cycle of medicines.
A PhD in immunology/allergology followed the initial degree in pharmacy, thereafter postdoctoral experience at an industrial research institute (AT), at the University of Southampton (UK) and at the National Institutes of Health (USA). The focus on the regulatory role started with a dual research/regulatory position at the US Food and Drug Administration (FDA).
Ilona Reischl has been the longstanding Austrian member of the European Medicines Agency Biologics Working Party and the Committee for Advanced Therapies, where she has been elected as chair in 2023. A keen interest in innovation has led to active involvement in manufacturing, procedural and scientific issues pertaining to biotech products in general and ATMPs in particular. Current additional regulatory activities focus on the interface of medicinal products and medical devices, including in vitro diagnostics during the life-cycle of medicines.